BBA
TCRT icon

Baker Bros. Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Baker Bros. Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,262
Closed -$2.27M – 134
2015
Q2 		$2.27M Hold
1,262
– – 0.02% 99
2015
Q1 		$2.04M Sell
1,262
-29
-2% -$43K 0.02% 105
2014
Q4 		$982K Sell
1,291
-340
-21% -$180K 0.01% 115
2014
Q3 		$646K Hold
1,631
– – 0.01% 104
2014
Q2 		$986K Hold
1,631
– – 0.01% 98
2014
Q1 		$1.12M Sell
1,631
-64
-4% -$42.9K 0.01% 96
2013
Q4 		$1.1M Hold
1,695
– – 0.02% 88
2013
Q3 		$1M Hold
1,695
– – 0.01% 78
2013
Q2 		$536K Buy
+1,695
New +$471K 0.01% 72

Other funds holding TCRT

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baker Bros. Advisors's TCRT Position: Q3 2015 in Review

Baker Bros. Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2015, closing a stake of 1,262 shares — an estimated $2.27M sold.

Baker Bros. Advisors first reported a position in TCRT in Q2 2013 and held it in 9 quarters. The position peaked at $2.27M in Q2 2015. 138 funds tracked by Wall St. Rank hold TCRT as of Q3 2015.

  • Baker Bros. Advisors reported no remaining Alaunos Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,262 Alaunos Therapeutics shares in Q3 2015, an estimated $2.27M.
  • Baker Bros. Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 9 quarters.
  • Baker Bros. Advisors's Alaunos Therapeutics position peaked at $2.27M in Q2 2015.
  • 138 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2015.

Based on Baker Bros. Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.